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Objective. To assess the prevalence and identiﬁed associated risk factors for precancerous cervical cancer lesions among HIV-
infected women in resource-limited settings in Kenya. Methods. HIV-infected women attending the ART clinic at the Nazareth
Hospital ART clinic between June 2009 and September 2010. Multivariate logistic regression model with odds ratios and 95%
conﬁdence intervals (CI) were estimated after controlling for important covariates. Result.At o t a lo f7 1 5w o m e nw e r es c r e e n e df o r
cervicalcancer.Themedianageoftheparticipantswas40years(range18–69years).Theprevalenceofprecancerouslesions(CINI,
CINII, CIN III, ICC) was 191 (26.7%). After controlling for other variables in logistic regression analysis, cervical precancerous
lesionswereassociatedwithnotbeingonARTtherapy;wherebynon-ARTwere2.21timesmorelikelytohaveprecancerouslesions
than ART patients [(aOR) = 2.21, 95% CI (1.28–3.83)]. Conclusion. The prevalence of precancerous cervical lesions was lower
than other similar settings. It is recommended that cancer screening of HIV-infected women should be an established practice.
AvailabilityandaccessibilityoftheseservicescanbedonethroughtheirintegrationintoHIV.PromptinitiationofHAARTthrough
an early enrollment into care has an impact on reducing the prevalence and progression of cervical precancerous lesions.
1.Background
Cervical cancer is the second most common malignancy
and accounts for the greatest number of deaths from can-
cer in women worldwide [1]. Human immunodeﬁciency
virus (HIV) infection also represents a tremendous health
burden worldwide. Cervical cancer was made an acquired
immunodeﬁciency syndrome (AIDS-) deﬁning illness in
1993 [2]. In 2005, there were almost 260,000 deaths from
cervical cancer and more than 500,000 new cases worldwide.
Women in developing countries are at greater risk of death
from cervical cancer primarily because few have access to the
screening and treatment services that have greatly reduced
mortality in the industrialized world over the past four
decades. About 75% of women in industrialized countries
has been screened for cervical cancer in the previous ﬁve
years, compared to less than 5% in developing countries
[3]. According to WHO (1986), it has been estimated that
only about 5% of women in developing countries has been
screened for cervical dysplasia in the past 5 years, compared
with 40% to 50% of women in developed countries [4].
Research ﬁndings suggest that HIV-induced immunodeﬁ-
ciency predisposes to cervical intraepithelial neoplasia (CIN)
orcervicalcarcinomabyfacilitatingtheexpressionofacausal
agent [5–8]. The public health importance of assessing the
interaction between HIV and HPV infection with respect to
cervical disease is suggested by increased rates of dysplasia
persistence and recurrence among HIV-positive women and
shorter survival for women with HIV infection and cervical
cancer [9].2 AIDS Research and Treatment
HIV-positive women have a higher prevalence and in-
cidence of cervical precancerous lesions than HIV negative
women. HIV-positive women have a 2-fold to 4-fold greater
rate of HPV infection than HIV-negative women. The prev-
alence of HPV among HIV-positive women is associated
strongly with CD4 counts and HIV viral load (VL) [10,
11]. Highly active antiretroviral therapy (HAART) has been
shown to decrease HIV viral loads, increase CD4 cell
counts, and decrease most opportunistic infections. Since
the introduction of HAART there has been a decline in
certain malignancies in HIV-infected individuals [12, 13].
However, studies on the impact of HAART on the natural
history of cervical squamous intraepithelial lesions (SILs)
have produced inconsistent results [14, 15]. In HIV-infected
women, there is an increased risk of HPV infection and
squamous intraepithelial lesions (SIL), the precursor of
cervical cancer [16, 17] .T h e r ei ss t i l ll i m i t e de v i d e n c ef o r
understandingthenaturalhistoryandepidemiologyofHPV-
induced cervical cancer in HIV-infected women. Therefore
this study may assist policy makers to develop guidelines
for prevention and treatment strategies for cervical cancer
among HIV-infected women which is largely based on
limited evidence, or in the case of resource limited settings,
which currently are completely lacking. The objective of the
study was to assess prevalence and associated risk factors for
precancerous cervical lesions in HIV-infected women within
resource-limited settings in Kenya.
2. Methods
The study site was a faith-based hospital oﬀering compre-
hensive care and treatment to approximately 4,000 HIV-
infectedpatients.ThestudysitewaslocatedinCentralKenya,
Kiambu district which has a HIV prevalence of 4%. The
study population constituted eligible women attending the
ART treatment clinics. None of the patients had evidence
of Kaposi sarcoma or non-Hodgkin lymphoma. Eligibility
criteria included being aged 18–69 years and having no
current or past history of cervical disease. Women, eighteen
years and older, who were on followup for their HIV-positive
status, were screened for cervical cancer using the Visual
Inspection with Lugol’s Iodine (VILI) technique.
Data on sociodemographic status, sexual behavior, his-
tory of a sexually transmitted infection (STI), obstetrics,
and gynecology history (parity) was obtained from patient
medical records as part of the routine quality improvement
activities; CD4 count data and HAART status were also
extracted from clinical records. Clients were referred to the
clinician where a pelvic examination was conducted using a
sterile speculum examination. Visual inspection with lugol’s
iodine (VILI) was used as the screening technique. A positive
VILI test necessitated a cervical biopsy; this was preserved
in a sterile container using formalin as the ﬁxative and the
biopsies were then taken for histology.
The histology result upon biopsy would turn out to be
either negative for intraepithelial lesion (IEL), active/chronic
cervicitis, precancerous lesions (CIN I, CIN II, or CIN
III/CIS), or cervical cancer (squamous cell or adenocarci-
noma) which was either diﬀerentiated (well, moderately,
poorly diﬀerentiated) cervical cancer. The cervical cancer
clients were clinically staged using the 1986 International
Federation of Gynecology and Obstetrics (FIGO) architec-
tural staging system [18].
Their participation in the screening in no way aﬀected
access to, or provision of, comprehensive HIV/AIDS care as
this was a standard of care at the clinic.
2.1. Statistical Analysis. Statistical analysis was carried out
using STATA 11 (StataCorp LP, College Station, TX, USA).
Descriptive statistics (medians and proportions) were used
to characterize the variables. Bivariate (unadjusted) analysis
was performed to identify factors signiﬁcantly associated
with the precancerous lesions. Odds ratios (OR), 95% conﬁ-
dence intervals (CI) and two-tailed P values were calculated.
Statistical tests used were the Chi-square and Fischer’s
exact tests for proportions, median test, and Wilcoxon
rank test for continuous variables. Variables found to be
statistically signiﬁcant (P<0.05) on unadjusted analysis
were included in a multivariate logistic regression model
through a combination of forward and backward stepwise
methods.
3. Result
3.1. Sociodemographic Characteristics of the Study Partici-
pants. All the 715 HIV-positive women attending the clinic
between June 2009 and December 2010 were included for
this study. The median age of the participants was 40
years (range 18–69 years). About 589 (85.5%) were in the
reproductive age group (15–49) years. Regarding the parity,
555 (94%) have ≥1 child. About 645 (90.3%) were ever
married and 53 (7.4%) were single (Table 1).
3.2. Clinical and Reproductive Characteristics. The majority
of participants were in WHO stage III 316 (44%) and
210 (29.2%) in WHO stage IV (Table 1). Concerning the
baseline CD4 count, 273 (97.5%) ART clients and 7 (2.5%)
preART cases were below 200/mm3 while 245 (71.9%) ART
and 96 (28.1%) of Pre-aRT cases were above 200/mm3.
About 90 (91.8%) Pre-ART and 8 (8.2%) ART of the study
cases were below 200 in their current CD4 count and 488
(82.9%) ART and 100 (17.1%) Pre-ART cases were ≥200 in
their current CD4 (Table 2). The median and mean baseline
CD4 cell count were 228.0/mm3 and 251/mm3 (range 1–
1547.0/mm3). The median and mean current CD4 cell count
were 438.0/mm3 and 458/mm3 (range 5–1547.0/mm3).
About 578 (84.3%) women with HIV infection were on
antiretroviral therapy (ART). About 642 (92.6%) of the
HIV-infected women were in followup period of ≥1y e a r .
About 610 (85.4%) of the participants did not have any
history of abortion and 104 (14.6%) had history of abortion
at least once in life time. The prevalence of precancerous
lesions (CIN I, CIN II, CIN III, and ICC) was 191 (26.7%)
(Table 1).
3.3. Factors Associated with Precancerous Cervical Cancer
Lesions in HIV-Infected Women. In the bivariate analysis
(Table 3), only two variables are found to be associatedAIDS Research and Treatment 3
Table 1: Sociodemographic, clinical, and reproductive characteristics of HIV+ women screened for cervical cancer at Nazareth Hospital.
Variables Sample size (n) Percentage (%) Mean (SD)
HAART status (n = 686)
Yes 108 15.7 —
No 578 84.3 —
Presence of precancerous lesions (n = 715)
Negative 524 73.3 —
Positive 191 26.7 —
Marital status (n = 714)
Deceased 10 1.4 —
Married 645 90.3 —
Separated 6 0.8 —
Single 53 7.5 —
Age (n = 689) 40 (8.72)
<29 57 8.27 —
30–39 302 43.83 —
40–49 230 33.38 —
50–59 77 11.18 —
60–69 23 3.34 —
Baseline CD4 (n = 621) 250 (189)
<200 280 45.0 —
>200 341 55.0 —
Current CD4 (n = 686) 458 (236)
<200 98 14.2 —
>200 588 85.8 —
WHO staging (n = 692)
Stage 1 80 11.6 —
Stage 2 88 12.7 —
Stage 3 316 45.7 —
Stage 4 208 30.0 —
History of abortion (n = 714)
None 610 85.4 —
≥1 104 14.6 —
Parity (n = 591) 2.81 (1.95)
03 6 6 . 0 —
1-2 264 44.6 —
>2 291 49.4 —
Duration of followup in care (n = 693) 2.62 (1.54)
<1 year 51 7.4 —
1–3 years 443 63.9 —
4–6 years 199 28.7 —
Histology results (n = 191)
Normal 112 58.6
CIN 1 35 18.3
CIN 2 20 10.5
CIN 3 17 8.9
ICC 7 3.7
Note: SD stands for standard deviation.4 AIDS Research and Treatment
Table 2: CD4 and ART characteristics of HIV+ women screened
for cervical cancer in Nazareth Hospital.
CD4 count on ART
No Yes
Baseline CD4 count (n = 568)
<200 7 (2.5) 273 (97.5)
≥200 96 (28.1) 245 (71.9)
Current CD4 count (n = 686)
<200 8 (8.2) 90 (91.8)
≥200 100 (17.1) 488 (82.9)
withprecancerouslesions.ThosewomenwhosecurrentCD4
count was less than 200 were 1.6 times more likely to have
precancerous lesions than those patients above 200 current
CD4 count [crude odds ratios (cOR) = 1.61, 95% CI (1.02–
2.53)]. Non-ART patients were 2.2 times more likely to
have precancerous cervical lesions than those patients on
ART [crude odds ratios (cOR) = 2.23, 95% CI (1.29–3.86)].
In multivariate analysis after controlling other variables,
only non-ART patients were 2.21 times more likely to have
precancerous lesions than patients on ART patient [adjusted
odds ratios (aOR) = 2.21, 95% CI (1.28–3.83)].
4. Discussion
According to the World Health Organization (WHO),
invasive cervical cancer (ICC) is the second most common
cancer in women worldwide and is more frequent in low-
income countries [19]. Recent guidelines recommend that,
following two initial normal Pap-smears at a 6-month inter-
val, all HIV-positive women should undergo annual cervical
cytologic examination. In addition, it is recommended that
all immunosuppressed women with atypical squamous cells
undergo colposcopy [20]. In our study the prevalence of
precancerous lesions was 26.7% (191). In other studies
among HIV-infected women in Lusaka, Zambia was 79%
prevalence of high-grade squamous intraepithelial lesions
(HSIL) of the cervix [21] and the high prevalence of HPV-
DNA in Zambia study (97.2% for any HPV and 90.3%
for any HR-HPV) [22]. In Guinea, overall human papillo-
mavirus prevalence was 50.8% (78.5% and 47.9% among
women with and without cervical abnormalities, resp.) [23].
A recent meta-analysis shows that the HPV prevalence was
56.6% in Africa, 31.1% in Asia, 32.4% in Europe, 31.4% in
North America, and 57.3% in South/Central America [24].
Although the mechanism by which HIV increases risk of
cervical cancer is not completely understood, studies suggest
that HIV-induced immunosuppression leads to an inability
to control the expression of HPV and the production of HPV
oncoproteins E6 and E7 [25, 26] and the risk appears to be
associated with increased HPV persistence that may result
from immunosuppression related to HIV. Furthermore, the
risk is greater in women with CD4 counts less than 200 cells
per microliter and in those with high plasma HIV RNA levels
[27]. Studies have shown that HIV-1 infection is associated
with an increased rate of HPV infection, mainly restricted
to HR-HPV types which are the cause of invasive cancer
of the cervix [28–30]. Several studies conducted in sub-
Saharan Africa indicate that among African women, being
HIV infected was associated with a high risk of presenting
squamous intraepithelial lesions of the cervix, with ORs
ranging from 4.4 to 17 depending on the grade of the lesion
and other factors [28, 30–33]. Yet, many case-referent studies
conducted in Uganda, Rwanda, and Cˆ ote d’Ivoire failed to
demonstrate any signiﬁcant association between HIV and
ICC,withORsrangingfrom1.1to1.6[34–37].Case-referent
studies in South Africa also found a signiﬁcant association
with ORs of 1.6 and 1.6 [38, 39]. In another case-referent
study conducted in Kenya, HIV-positive women were also
more likely to be HPV infected compared to HIV-negative
women (OR = 3.1) [40]. A cross-sectional study determined
the prevalence of HPV infection, HIV infection, and cervical
cytological abnormalities in Ugandan women presenting to
a sexually transmitted infection clinic [41]a n df o u n d4 9
cases of HPV infection among 106 women with cervical
swabs adequate for HPV testing (46.2%). Similarly, a study
realizedinZambiaamong145HIV-infectedwomenofwhich
93.8% had abnormal Pap smears [22]. In other study of
women initiating ARV therapy recorded an exceptionally
high prevalence of cervical abnormalities (66%) [42]. This
ﬁnding has implications for future interventions in the
implementation of prophylactic HPV vaccines to be the part
o fc a r ea n ds u p p o r tp r o g r a m m ef o rH I V - i n f e c t e dw o m e n .
In our study those women whose current CD4 count
was less than 200 were 1.6 times more likely to have pre-
cancerous cervical cancer lesions than those patients with
a current CD4 count above 200. However, regarding the
eﬀectofimmunefunction,previousstudieshaveconsistently
demonstrated that the amount of CD4 cell count is a sig-
nificant predictor for having or developing CIN [43–45].
Given the low CD4 counts in our study population, severe
immunosuppression is the most likely explanation for the
high prevalence of cervical abnormalities and precancerous
cervical lesions detected.
In HIV infection, lower CD4 counts have been associated
with a higher prevalence of HPV infection [5, 46] and persis-
tentsheddingofHPVDNA[47,48].HPVviralloadincreases
with immune suppression, likely accounting for greater
facility of HPV DNA detection [46]. In this study there
was a positive association between having a CD4 count of
<200. This suggests that as the CD4 count declines, vigilant
followup of the anogenital tract, particularly with cervical
cytological and/or histological screening, is warranted [49].
In our analysis non-ART patients were 2.21 times more
likely to have CIN infection than ART patients. Similar ﬁnd-
ingshavebeendocumentedinotherstudies.AsHIV-infected
women continue to live longer with ART support, albeit
in a moderately immunosuppressed state, they may be at
increased risk for CIN and invasive cervical cancer [11,
50]. However, studies on the impact of HAART on the
natural history of cervical squamous intraepithelial lesions
have produced inconsistent results [14, 15]. Antiretroviral
therapy (ART) for PLHIV provides a golden opportunity to
increase cervical screening through the integration of ART
serviceswithfrequentscreeningofwomenforcervicalcancerAIDS Research and Treatment 5
Table 3: Unadjusted and adjusted odds ratios of the multilevel logistic regression estimates for factors associated with precancerous cervical
cancer lesions among HIV+ at Nazareth Hospital.
Characteristics Cervical cancer screening P value Unadjusted/cOR Adjusted/aOR P value
Negative Positive
Current CD4 count 0.038
<200 78 (72.2) 30 (27.8) 1.61 (1.02–2.53)
≥200 431 (87.5) 147 (81.3) 1.00
On HAART 0.003 0.005
Yes 91 (84.2) 17 (15.8) 1.00 1.00
No 404 (69.8) 174 (30.2) 2.23 (1.29–3.86) 2.21 (1.28–3.83)
[21, 50]. Starting HAART has an impact on reducing the
incidence and progression and facilitating the regression of
CIN infection and cervical abnormalities.
The study should be interpreted in light of the strength
and limitations. Major strengths of our study include the
large number of women, high participation, and reliance on
cost-eﬀective, simple, timely VILI testing. The Limitations
include but not limited to the lack of information on some of
the variables that can predict cervical cancer in HIV-infected
women like the use of oral contraceptives or estrogens,
information on sexual behavior, and smoking [49] and the
cross-sectional nature of this study allows the possibility for
confounding so it is diﬃcult to reach any causality. This may
hence hinder the generalizability of our ﬁndings.
5. Conclusion
In this study, the prevalence of CIN was 26.7 percent (191)
which is lower than other ﬁndings reported in Africa. Those
patients who were not on antiretroviral therapy were more
likely to have CIN diagnosis than who were on antiretroviral
therapy. Therefore regular screening of HIV-infected women
is of paramount importance. Starting ART acts as leverage
for cancer screening and majority of ART patients are likely
not to progress to cervical cancer as demonstrated by this
study. Conducting well-designed prospective cohort study
to study natural history of cervical neoplasia among HIV-
infected women in developing country settings is warranted.
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